Aadi Bioscience, Inc. (AADI)
NASDAQ: AADI · Real-Time Price · USD
2.185
-0.025 (-1.13%)
Mar 6, 2025, 12:30 PM EST - Market open
Company Description
Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes.
Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa.
The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway.
Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.
Aadi Bioscience, Inc.
| Country | United States |
| Founded | 2011 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 89 |
| CEO | David Lennon |
Contact Details
Address: 17383 Sunset Boulevard, Suite A250 Pacific Palisades, California 90272 United States | |
| Phone | 424 744 8055 |
| Website | aadibio.com |
Stock Details
| Ticker Symbol | AADI |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001422142 |
| CUSIP Number | 00032Q104 |
| ISIN Number | US00032Q1040 |
| Employer ID | 61-1547850 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. David J. Lennon Ph.D. | President, Chief Executive Officer and Director |
| Dr. Neil P. Desai Ph.D. | Founder and Director |
| Scott M. Giacobello CPA | Chief Financial Officer, Treasurer, Investor Relations and Corporate Communications |
| Bryan Ball | Chief Technical Operations Officer |
| Dr. David Dornan Ph.D. | Chief Scientific Officer |
| Stephen M. Rodin J.D. | Senior Vice President of Legal and General Counsel |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 5, 2025 | SCHEDULE 13D/A | Filing |
| Mar 4, 2025 | SCHEDULE 13D/A | Filing |
| Mar 4, 2025 | 8-K | Current Report |
| Mar 3, 2025 | 144 | Filing |
| Mar 3, 2025 | 144 | Filing |
| Mar 3, 2025 | 144 | Filing |
| Feb 24, 2025 | SCHEDULE 13D/A | Filing |
| Feb 19, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Feb 18, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |